{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:12:36Z","timestamp":1787886756489,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR066218"],"award-info":[{"award-number":["AR066218"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003227","name":"Osteogenesis Imperfecta Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bone.2017.06.004","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T17:31:42Z","timestamp":1496856702000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine"],"prefix":"10.1016","volume":"103","author":[{"given":"Brya G.","family":"Matthews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector Leonardo","family":"Aguila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Kyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-8249","authenticated-orcid":false,"given":"Danka","family":"Grcevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Kalajzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2017.06.004_bb0005","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2017.06.004_bb0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1210\/endo.143.5.8807","article-title":"Osteoblastic response to the defective matrix in the osteogenesis imperfecta murine (oim) mouse","volume":"143","author":"Kalajzic","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2017.06.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0040007","article-title":"ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta","volume":"4","author":"Lisse","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bone.2017.06.004_bb0020","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0025","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-\u03b1 induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bone.2017.06.004_bb0030","first-page":"47","article-title":"Anesthetic implications for the patient with osteogenesis imperfecta","volume":"78","author":"Oakley","year":"2010","journal-title":"AANA J."},{"key":"10.1016\/j.bone.2017.06.004_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1203\/PDR.0b013e31815efd63","article-title":"High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment","volume":"63","author":"D'Eufemia","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0040","first-page":"1","article-title":"Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-\u03b1","author":"Brunetti","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2017.06.004_bb0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1359\/jbmr.1999.14.2.264","article-title":"The material basis for reduced mechanical properties in oim mice bones","volume":"14","author":"Camacho","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0050","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","article-title":"Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta","volume":"90","author":"Chipman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2017.06.004_bb0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s002239900412","article-title":"Bone geometry and strength measurements in aging mice with the oim mutation","volume":"62","author":"McBride","year":"1998","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2017.06.004_bb0060","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2353\/ajpath.2010.090704","article-title":"Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine","volume":"176","author":"Li","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2017.06.004_bb0065","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/jcb.21337","article-title":"Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the Oim\/Oim mouse model of osteogenesis imperfecta","volume":"102","author":"Zhang","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2017.06.004_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1359\/JBMR.051007","article-title":"Identification of multiple osteoclast precursor populations in murine bone marrow","volume":"21","author":"Jacquin","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jbmr.1822","article-title":"Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery","volume":"28","author":"Jacome-Galarza","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0080","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2017.06.004_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2017.06.004_bb0090","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1359\/JBMR.051207","article-title":"Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta","volume":"21","author":"Land","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0095","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0100","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bone.2017.06.004_bb0105","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap\u2212\/\u2212 mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0110","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bone.2016.06.005","article-title":"Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1+\/mov13 mouse model of type I osteogenesis imperfecta","volume":"90","author":"Jacobsen","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.06.004_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.06.004_bb0130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2017.06.004_bb0135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0b013e328356d212","article-title":"Effects of anti-tumor necrosis factor a agents on bone","volume":"24","author":"Kawai","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bone.2017.06.004_bb0140","first-page":"192","article-title":"PCR genotyping of oim mutant mice","volume":"21: 190","author":"Saban","year":"1996","journal-title":"Biotechniques"},{"key":"10.1016\/j.bone.2017.06.004_bb0145","doi-asserted-by":"crossref","DOI":"10.3791\/2809","article-title":"Identification and analysis of mouse erythroid progenitors using the CD71\/TER119 flow-cytometric assay","author":"Koulnis","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.bone.2017.06.004_bb0150","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1182\/blood-2003-11-4011","article-title":"Hematopoiesis is severely altered in mice with an induced osteoblast deficiency","volume":"103","author":"Visnjic","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2017.06.004_bb0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/art.11419","article-title":"Systemic tumor necrosis factor \u03b1 mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor \u03b1\u2013transgenic mice","volume":"50","author":"Li","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2017.06.004_bb0160","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J."},{"key":"10.1016\/j.bone.2017.06.004_bb0165","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jbmr.2125","article-title":"Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-\u03b1-induced inflammation and bone loss","volume":"29","author":"Yoshitaka","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.bone.2013.06.002","article-title":"Chronic low dose tumor necrosis factor-alpha (TNF) suppresses early bone accrual in young mice by inhibiting osteoblasts without affecting osteoclasts","volume":"56","author":"Gilbert","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.06.004_bb0175","doi-asserted-by":"crossref","first-page":"675108","DOI":"10.1155\/2014\/675108","article-title":"Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-alpha and its soluble receptors during the course of therapy with etanercept and infliximab","volume":"2014","author":"Schulz","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bone.2017.06.004_bb0180","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.bone.2017.06.004_bb0185","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.3892\/mmr.2014.2127","article-title":"Induced production of anti-etanercept antibody in collagen-induced arthritis","volume":"9","author":"Yi","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bone.2017.06.004_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086757","article-title":"Sex and genetic factors determine osteoblastic differentiation potential of murine bone marrow stromal cells","volume":"9","author":"Zanotti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2017.06.004_bb0195","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.intimp.2015.03.048","article-title":"Expression of receptor activator of nuclear factor-kappaB ligand is related to sex differences in collagen-induced arthritis","volume":"28","author":"Ding","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bone.2017.06.004_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11657-011-0054-z","article-title":"Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta","volume":"6","author":"Wekre","year":"2011","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2017.06.004_bb0205","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s11999-015-4268-z","article-title":"Are changes in composition in response to treatment of a mouse model of osteogenesis imperfecta sex-dependent?","volume":"473","author":"Boskey","year":"2015","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0210","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2017.06.004_bb0215","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2016.09.013","article-title":"Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model","volume":"93","author":"Perosky","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.06.004_bb0220","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bone.2013.01.023","article-title":"Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone","volume":"53","author":"Vanleene","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.06.004_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/boneres.2014.42","article-title":"Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta","volume":"3","author":"DiGirolamo","year":"2015","journal-title":"Bone Res."},{"key":"10.1016\/j.bone.2017.06.004_bb0230","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10439-013-0793-7","article-title":"Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model","volume":"41","author":"Yao","year":"2013","journal-title":"Ann. Biomed. Eng."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821730193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821730193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:39:52Z","timestamp":1757612392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821730193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":46,"alternative-id":["S875632821730193X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.06.004","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}